1. Home
  2. TBPH vs CYRX Comparison

TBPH vs CYRX Comparison

Compare TBPH & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

N/A

Current Price

$17.03

Market Cap

908.9M

Sector

Health Care

ML Signal

N/A

Logo CryoPort Inc.

CYRX

CryoPort Inc.

N/A

Current Price

$16.51

Market Cap

814.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TBPH
CYRX
Founded
2013
1999
Country
United States
United States
Employees
N/A
1100
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
908.9M
814.9M
IPO Year
2013
2008

Fundamental Metrics

Financial Performance
Metric
TBPH
CYRX
Price
$17.03
$16.51
Analyst Decision
Buy
Strong Buy
Analyst Count
6
8
Target Price
$18.40
$13.31
AVG Volume (30 Days)
345.7K
436.7K
Earning Date
05-04-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
279.13
156.22
EPS
N/A
N/A
Revenue
$15,386,000.00
$176,177,000.00
Revenue This Year
$8.46
$11.06
Revenue Next Year
N/A
$8.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.08
$7.61
52 Week High
$21.03
$17.20

Technical Indicators

Market Signals
Indicator
TBPH
CYRX
Relative Strength Index (RSI) 56.38 56.83
Support Level $16.80 $14.55
Resistance Level $17.11 $16.87
Average True Range (ATR) 0.06 0.59
MACD -0.01 -0.02
Stochastic Oscillator 15.69 69.08

Price Performance

Historical Comparison
TBPH
CYRX

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

About CYRX CryoPort Inc.

CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.

Share on Social Networks: